Supercharging An ADC Program With SOTIO CEO Dr. Radek Špíšek
SOTIO isn't your typical single-molecule, single-platform biopharma. Since its inception, the company has supported 14 clinical trials of oncology therapeutics developed leveraging multiple platform technologies. On this episode of The Business of Biotech, SOTIO Global CEO Radek Špíšek takes a deep dive into the development, HR, and funding strategies the company has deployed to build its IL-15, immune cell therapy, and antibody-drug conjugate candidates.
LISTEN TO THE PODCAST! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online X
Subscribe to Bioprocess Online